The occurrence of toxoplasmic encephalitis (TE) was studied among 19,598 and 17,016 patients enrolled in the French Hospital Database on human immunodeficiency virus whose CD4 cell counts decreased to р 6 200 ϫ 10 cells/L before (1992)(1993)(1994)(1995) or after (1996-1998) the availability of highly active antiretroviral therapy, respectively. The incidence of TE decreased from 3.9 cases per 100 person-years in the first period (95% confidence interval [CI], 3.7-4.1) to 1.0 cases per 100 person-years in the second period (95% CI, 0.9-1.1). After adjustment for known risk factors for TE, patients who received cotrimoxazole prophylaxis had a lower risk of TE (adjusted relative hazard, 0.6 and 0.5, respectively, for the first and second periods;
200 ϫ 10 cells/L before (1992-1995) or after (1996-1998) the availability of highly active antiretroviral therapy, respectively. The incidence of TE decreased from 3.9 cases per 100 person-years in the first period (95% confidence interval [CI], 3.7-4.1) to 1.0 cases per 100 person-years in the second period (95% CI, 0.9-1.1). After adjustment for known risk factors for TE, patients who received cotrimoxazole prophylaxis had a lower risk of TE (adjusted relative hazard, 0.6 and 0.5, respectively, for the first and second periods;
). For patients treated with P ! .001 cotrimoxazole at inclusion, discontinuation of cotrimoxazole increased the risk of TE in both periods (adjusted relative hazard, 4.8 and 4.2, respectively;
). Among patients whose CD4 cell counts increased to P ! .001 1 cells/L while undergoing highly active antiretroviral therapy, the incidence of TE was 0.1 cases per 6 200 ϫ 10 100 person-years (95% CI, 0.0-0.2) and was not increased by discontinuation of cotrimoxazole.
Toxoplasmic encephalitis (TE) is a life-threatening CNS infection observed in the later stages of HIV infection [1] , especially in patients with CD4 cell counts of р cells/L [2] [3] [4] . Although never demonstrated 6 100 ϫ 10 in intention-to-treat analyses, the efficacy of cotrimoxazole in TE prophylaxis has been suggested by during-treatment analyses of randomized trials designed to examine prophylaxis of Pneumocystis carinii pneumonia [5] [6] [7] [8] [9] [10] [11] .
The aim of this study was to assess the incidence and risk factors for TE in 2 periods, namely before the availability of protease inhibitors (from 1 January 1992 through 31 December 1995) and after the availability of protease inhibitors (from 1 January 1996 through 31 December 1998), by use of the French Hospital Database on HIV (FHDH). Although information on Toxoplasma serostatus is not collected in the FHDH, the estimated seroprevalence of Toxoplasma gondii in France is 160% [12, 13] , and the database provides an opportunity to investigate a disease whose incidence has fallen markedly since the advent of highly active antiretroviral therapy (HAART). Analyses of risk factors for TE focused on the effect of cotrimoxazole prophylaxis and its discontinuation on TE occurrence in the 2 periods, after adjustment for other risk factors.
METHODS
The database. The FHDH is a large prospective cohort study that enrolls HIV-infected patients aged у15 years in 68 French University hospitals. The enrollment criteria are documented HIV-1 or HIV-2 infection and written informed consent. Trained research assistants use the French Ministry of Health DMI2 software to collect clinical and biological data (since July 1996, data regarding plasma virus load have been collected) prospectively at inclusion and at each visit or hospital admission for an HIV-related clinical event or a new treatment prescription, or at least every 6 months, on standardized forms.
Patients. Protease inhibitors were gradually prescribed after late March 1996 in France. To compare the period preceding with the period following protease inhibitor availability, we defined 2 periods: 1 January 1992 through 31 December 1995, and 1 January 1996 through 31 December 1998. In each period, the study population was restricted to patients with CD4 cell counts of р cells/L on at least 1 occasion. The in- 6 200 ϫ 10 clusion date in the study was the first date that the patient had a CD4 cell count р cells/L in the relevant period, 6 200 ϫ 10 regardless of CD4 cell counts before that period. Therefore, a given patient could be included in both periods. Only first occurrence of TE was considered, and patients were excluded if they had had a first episode of TE before the inclusion date.
Diagnosis of TE was based on information provided by physicians in each hospital, according to the 1993 classification of the Centers for Disease Control and Prevention [14] . All diagnoses of TE, both definite (neuropathological documentation) and presumptive (clinical and neuroradiological signs, including local serological data and response to specific therapy), were considered for the study.
Statistical analysis. The incidence of TE after the inclusion date in each period was calculated by dividing the number of patients who had a first episode of TE by the number of personyears at risk. Follow-up times were calculated from baseline to the first episode of TE or to the date of death, the last followup visit, or the end of the period, whichever occurred first.
Cox's regression model was used for each period to evaluate the impact of cotrimoxazole prophylaxis after adjustment for other TE risk factors [15] . Antiretroviral therapy and cotrimoxazole prophylaxis were analyzed as time-dependent covariates, to avoid a survivor treatment selection bias, and were assessed with an intent-to-treat approach [16] . Antiretroviral regimen groups were nucleoside reverse transcriptase inhibitor monotherapy, nucleoside reverse transcriptase inhibitor polytherapy, or HAART. A patient could have different antiretroviral regimens during follow-up. Occurrence of a first AIDSdefining event and changes in CD4 cell count during each period were also analyzed as time-dependent covariates [17] . Three groups of patients were created on the basis of changes in the CD4 cell count: those whose CD4 cell count at inclusion and throughout follow-up remained 1 cells/L; those 6 100 ϫ 10 whose CD4 cell count at inclusion or during follow-up decreased to р cells/L and remained less than this value; 6 100 ϫ 10 and those whose CD4 cell count at inclusion or during followup decreased to р cells/L but increased to more than 6 100 ϫ 10 this value thereafter. Other usual covariates (see table 1) were also taken into account. To compare the 2 periods, before and after protease inhibitor availability, the same variables were included in multivariate Cox models. Therefore, each variable associated with the risk of TE ( ) in univariate analysis P ! .20 was included in both multivariate models.
Then, for each period, to evaluate the impact of discontinuing primary prophylaxis with cotrimoxazole, analyses were conducted of patients receiving cotrimoxazole prophylaxis at inclusion. Risk factors for TE were assessed by using Cox's regression model, with antiretroviral therapy, changes in the CD4 cell count, and cotrimoxazole discontinuation analyzed as time-dependent covariates [17] . We assumed that cotrimoxazole had been discontinued when the patient had completely stopped taking the drug at least 1 month before the onset of TE or the end of followup. Incidence was evaluated for patients receiving cotrimoxazole prophylaxis at inclusion according to the CD4 cell count, antiretroviral treatment, and discontinuation of cotrimoxazole prophylaxis in each period. To estimate 95% CIs, the normal distribution was used when the sample size and number of events were adequate; the Poisson distribution was used in other cases. When no events occurred, the exact upper limit of the CI for the incidence of TE was calculated by means of the binomial distribution [18] . Data were analyzed with SAS statistical software, version 6.12 (SAS Institute). During the period following the availability of protease inhibitors (1 January 1996 through 31 December 1998), 17,016 patients were included. The median CD4 cell count was cells/L (IQR, cells/L) at inclusion, and 6 6 109 ϫ 10 39-165 ϫ 10 the median nadir of CD4 cell count was /L (IQR, 6 69 ϫ 10 cells/L). Median follow-up was 24 months (IQR, Table 1 . Characteristics of HIV-infected patients, according to period of inclusion (before or after availability of protease inhibitors) and whether they did or did not develop toxoplasmic encephalitis (TE). 6 20 ϫ 10 cells/L (IQR, cells/L) at the date of the first episode 6 8-61 ϫ 10 of TE.
RESULTS

During
The baseline and follow-up characteristics of the patients who did and did not develop a first episode of TE during each period are shown in table 1; 7803 patients included in the second period had also been included in the first. Of these, 166 subsequently developed a first episode of TE. The baseline and follow-up characteristics of the patients included in both periods were not different from those of patients included only in the period following availability of protease inhibitors (data not shown).
Risk factors for TE. In both periods, multivariate analyses confirmed the predictive value of markers of immunosuppression (occurrence of a first AIDS-defining event or decrease in CD4 cell count to р cells/L during follow-up, par-6 100 ϫ 10 ticularly when the CD4 cell count remained р cells/ 6 100 ϫ 10 L thereafter) and of antiretroviral therapy (table 2) . Antiretroviral therapy reduced the risk of TE by 36%, in patients receiving nucleoside reverse transcriptase inhibitor polytherapy in the period before the availability of protease inhibitors, and by 34%, in patients treated with HAART in the period after the availability of protease inhibitors. During the second period, when the baseline plasma HIV RNA level was included in the multivariate analysis (5046 patients; 57 with TE), patients whose CD4 cell counts at inclusion or during the follow-up decreased to р cells/L and remained below this value 6 100 ϫ 10 and patients with higher plasma HIV RNA levels had a significantly higher probability of developing TE (relative hazard, 27.94; 95% CI, 11.91-65.51;
; and RH, 2.00 per 1-log 10 / P ! .001 mL increment; 95% CI, 1.35-2.95;
; respectively). P p .001 Cotrimoxazole prophylaxis reduced the risk of TE in both periods: by 36% in the first period and by 46% in the second. The risk of TE was also reduced in the second period by cotrimoxazole prophylaxis in the Cox model with inclusion of the baseline plasma HIV RNA level (RH, 0.47; 95% CI, 0.26-0.85;
). P p .01
In the period after availability of protease inhibitors, analyses of patients included only in this period and analyses of all patients of the period gave similar results (data not shown).
Impact of cotrimoxazole discontinuation. During the period before availability of protease inhibitors, 8669 patients were receiving cotrimoxazole prophylaxis at the date of inclusion, among whom 379 developed a first episode of TE; 3075 stopped taking cotrimoxazole prophylaxis during follow-up, among whom 207 subsequently developed a first episode of TE. In the period after the availability of protease inhibitors, 12,106 patients were receiving cotrimoxazole prophylaxis at the date of inclusion, of whom 195 developed a first episode of TE; 4627 stopped taking cotrimoxazole prophylaxis during follow-up, of whom 82 subsequently developed a first episode of TE. After adjustment, discontinuation of cotrimoxazole prophylaxis increased the risk of TE in both periods (RH, 4.81; 95% CI, 3.92-5.91; and RH, 4.21; 95% CI, 3.15-5.62). Results were similar when the analysis included the plasma HIV RNA level in the second period (3475 patients, 29 of whom had TE; RH, 3.13; 95% CI, 1.44-6.79).
Among the patients receiving cotrimoxazole at the date of inclusion, the incidence of TE decreased from the first period to the second; decreased among patients who started antiretroviral polytherapy during follow-up (nucleoside reverse transcriptase inhibitor polytherapy in the first period, HAART in the second), particularly among the most immunodeficient patients; and increased among patients whose CD4 cell counts at inclusion or during follow-up decreased to р cells/L (particularly 6 100 ϫ 10 among those whose counts remained р cells/L there-6 100 ϫ 10 after) (table 3). The incidence increased in patients who discontinued cotrimoxazole prophylaxis, but this increase was not observed in patients undergoing HAART whose CD4 cell counts increased to 1 cells/L during follow-up ( ). 6 200 ϫ 10 P p .45
DISCUSSION
The incidence of TE decreased from 3.9 cases per 100 personyears (95% CI, 3.7-4.1 cases per 100 person-years) in the period before availability of protease inhibitors to 1.0 cases per 100 person-years (95% CI, 0.9-1.1 cases per 100 person-years) after availability of protease inhibitors. In both periods, after adjustment for known risk factors for TE, patients who received cotrimoxazole prophylaxis (whatever the daily dose or treatment duration) were at a lower risk of TE than were other patients. Analysis restricted to the patients with cotrimoxazole prophylaxis at inclusion showed that discontinuation of cotrimoxazole increased the risk of TE. The incidence of TE was very low among patients with a sustained increase in CD4 cell counts to 1 cells/L during HAART, and no increase 6 200 ϫ 10 in incidence was found among these patients after discontinuation of cotrimoxazole.
Several limitations must be discussed in this study. Cases of TE were diagnosed by local physicians and were not validated by a validation committee. It is thus possible that some presumptive diagnoses of TE were incorrect, resulting in misclassification. Such misclassifications were probably balanced in the different groups and would lead only to an underestimation of the link between risk factors and TE. However, despite possible erroneous diagnoses, TE was common in the pre-HAART era, and its diagnosis in French university hospitals is based on the criteria recommended in the literature [14] .
The study was an observational analysis with prophylactic regimen given on a nonrandomized basis, and intolerance before inclusion was not analyzed. Patients who received cotrimoxazole before the date of inclusion, but not after, were classified as patients without cotrimoxazole prophylaxis during the studied period. Because adverse reactions to cotrimoxazole are associated with more rapid progression to AIDS and death [19] , this could have led to an overestimation of the risk of TE in the group of patients who had not received cotrimoxazole prophylaxis.
The fact that the seroprevalence of T. gondii is high in France can explain the high incidence of TE found in this study in both periods, in comparison with the lower incidence reported in other countries. However, we cannot rule out the possibility that the patients who continued to undergo cotrimoxazole prophylaxis were not fully compliant, and that the incidence of TE among these patients could have been overestimated.
Biases due to cotrimoxazole discontinuation as assessed in this study need to be discussed. In the group of patients with CD4 cell counts that decreased to and remained at р cells/L, ∼30% of the patients discontinued cotri-6 100 ϫ 10 moxazole prophylaxis. Because of the brief follow-up after discontinuation, the most likely explanation for the interruption of prophylaxis was the occurrence of an acute event. In addition, the incidence could have been overestimated in the group of patients who did not discontinue cotrimoxazole prophylaxis, because noncompliant patients were possibly included in this group of patients. Therefore, the association between discontinuation of cotrimoxazole prophylaxis and occurrence of TE could have been underestimated.
The groups of patients whose CD4 cell counts decreased to but did not remain at р cells/L and whose CD4 cell 6 100 ϫ 10 counts remained at 1 cells/L during all of the follow-6 100 ϫ 10 up included some patients whose CD4 cell counts subsequently increased and remained 1 cells/L. Because follow-up 6 200 ϫ 10 was not censored when the CD4 cell count increased to more than cells/L, some of the patients who discontinued 6 200 ϫ 10 cotrimoxazole prophylaxis did so after having reached CD4 cell counts of cells/L, explaining the 35% and 40% of 6 200 ϫ 10 the patients in these groups who discontinued cotrimoxazole prophylaxis despite lack of recommendations among patients with CD4 cell counts of 1 cells/L. 6 100 ϫ 10 Among patients whose CD4 cell counts increased and remained 1 cells/L, 150% stopped cotrimoxazole pro- 6 200 ϫ 10 phylaxis. Several studies have suggested that primary PCP prophylaxis can safely be discontinued in patients who have a sustained increase in their CD4 cell count to 1 cells/ 6 200 ϫ 10 L while receiving HAART. This is now validated by guidelines [20] , and it has been increasingly adopted by physicians, as shown by the very high frequency of cotrimoxazole discontinuation among those patients.
No prospective randomized trials have specifically evaluated the efficacy of cotrimoxazole for the prophylaxis of toxoplasmosis. In previously reported trials of prophylaxis of P. carinii pneumonia, most cases of toxoplasmosis occurred after discontinuation of cotrimoxazole prophylaxis in patients allocated to the cotrimoxazole group, meaning that the preventive efficacy of cotrimoxazole on TE could only be suggested by duringtreatment analyses and not clearly demonstrated by intentionto-treat analyses [5] [6] [7] [8] [9] [10] [11] . Other published studies have given conflicting results [2] [3] [4] [21] [22] [23] [24] . Prospective randomized trials are now difficult to conduct because of the marked decrease in the incidence of opportunistic infections since the advent of HAART [25, 26] . The FHDH, which comprises a substantial number of patients, contains a sufficient number of TE events, even during the HAART period. Our study, an observational analysis based on prospectively collected data during cotrimoxazole prophylaxis, further supports the efficacy of cotrimoxazole prophylaxis in prevention of TE, after adjustment for numerous prognostic factors, both before and during the HAART era. Discontinuation of cotrimoxazole prophylaxis was a risk factor for TE after adjustment for other risk factors in both periods, and the incidence of TE increased after cotrimoxazole discontinuation, especially among the most immunodeficient patients. When the CD4 cell count increased to and remained at 1 cells/L, the incidence of TE was markedly lower, 6 200 ϫ 10 and no effect of cotrimoxazole discontinuation was observed. Only 4 of 4917 patients developed an episode of TE after their CD4 cell count had increased to 1 cells/L while un- 6 200 ϫ 10 dergoing HAART during a total follow-up period of 5265 person-years. The incidence among these patients was very low, and it was similar before and after cotrimoxazole discontinuation. Because several studies have suggested that discontinuation of primary or secondary prophylaxis for P. carinii pneumonia is feasible for patients with CD4 cell counts of 1 cells/L while undergoing HAART [27] [28] [29] [30] [31] , our 6 200 ϫ 10 study shows that risk of TE is really very low for these patients when cotrimoxazole is stopped.
This study confirms the primary role of immunodeficiency in the occurrence of TE [2] [3] [4] and the efficacy of potent antiretroviral therapy in reducing the risk of opportunistic infections [25, 26] . Our results support the use of the most potent antiretroviral strategies, even for patients who remain strongly immunodeficient.
In conclusion, this prospective cohort study further supports the efficacy of cotrimoxazole prophylaxis in protection against TE, with a further protective effect of HAART and immune recovery, and a deleterious effect of cotrimoxazole discontinuation in immunodeficient patients. Because TE is associated with a high probability of early death, prophylaxis against toxoplasmosis and potent antiretroviral therapies are still necessary for strongly immunodeficient HIV-infected patients when im-munosuppression progresses. In contrast, discontinuation of cotrimoxazole prophylaxis seems feasible for patients who have a sustained increase in the CD4 cell count to more than cells/L during HAART. 6 200 ϫ 10
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